Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184764 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
A Phase 1 study, sponsored by Armata Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05184764 is a Phase 1 study that has completed, run by Armata Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT05184764, a Phase 1 study, has completed, sponsored by Armata Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus
Interventions
- OTHER Placebo
- BIOLOGICAL AP-SA02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2025-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05184764
The ClinicalTrials.gov registry entry for NCT05184764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Armata Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05184764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05184764 about?
NCT05184764 is a clinical study titled "Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia". Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With...
What is the current status of trial NCT05184764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-04-26. Estimated completion is 2025-01-14.
What interventions are being tested in trial NCT05184764?
The interventions under investigation include: Placebo (OTHER), AP-SA02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05184764?
This trial is sponsored by Armata Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.